These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 9380720)

  • 1. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.
    Weiner GJ; Liu HM; Wooldridge JE; Dahle CE; Krieg AM
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10833-7. PubMed ID: 9380720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
    Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
    Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
    Saha A; Baral RN; Chatterjee SK; Mohanty K; Pal S; Foon KA; Primus FJ; Krieg AM; Weiner GJ; Bhattacharya-Chatterjee M
    Cancer Immunol Immunother; 2006 May; 55(5):515-27. PubMed ID: 16044253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ
    J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
    Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
    J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen.
    Baral RN; Saha A; Chatterjee S; Foon KA; Krieg A; Weiner GJ; Bhattacharya-Chatterjee M
    Cancer Immunol Immunother; 2003 May; 52(5):317-27. PubMed ID: 12700947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of rats against Fasciola hepatica using crude antigens conjugated with Freund's adjuvant or oligodeoxynucleotides.
    Cervi L; Borgonovo J; Egea M; Chiapello L; Masih D
    Vet Immunol Immunopathol; 2004 Jan; 97(1-2):97-104. PubMed ID: 14700541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
    Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
    Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
    Jin JW; Tang SQ; Rong MZ; Zhang MQ
    Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.
    Kumar S; Jones TR; Oakley MS; Zheng H; Kuppusamy SP; Taye A; Krieg AM; Stowers AW; Kaslow DC; Hoffman SL
    Infect Immun; 2004 Feb; 72(2):949-57. PubMed ID: 14742540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells.
    Du HY; Xia SY; Song HF; Li N; Shang MM; Zou J; Wang QQ; Ou L; Sun X; Ji AG; Tang ZM
    Acta Pharmacol Sin; 2007 Oct; 28(10):1637-44. PubMed ID: 17883951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
    McCluskie MJ; Weeratna RD; Davis HL
    Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.
    Fonseca DM; Silva CL; Paula MO; Soares EG; Marchal G; Horn C; Bonato VL
    Immunology; 2007 Aug; 121(4):508-17. PubMed ID: 17433075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.
    Li WM; Bally MB; Schutze-Redelmeier MP
    Vaccine; 2001 Oct; 20(1-2):148-57. PubMed ID: 11567759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
    Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
    J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
    Adamsson J; Lindblad M; Lundqvist A; Kelly D; Holmgren J; Harandi AM
    J Immunol; 2006 Apr; 176(8):4902-13. PubMed ID: 16585586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.
    Warren TL; Dahle CE; Weiner GJ
    Clin Lymphoma; 2000 Jun; 1(1):57-61. PubMed ID: 11707814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.